Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Status:
Recruiting
Trial end date:
2026-12-07
Target enrollment:
Participant gender:
Summary
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab
administered subcutaneously (SC) in adult participants with symptomatic COPD with a history
of ≥ 2 moderate or ≥ 1 severe exacerbations of COPD in the 12 months prior to enrolment.
Participants should be receiving optimised treatment with inhaled maintenance therapy
(ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate)
throughout at least the last 3 months prior to enrolment.